Leopold Bertea

Company: Mendus

Job title: Chief Technology Officer

Seminars:

Panel Discussion: Ensuring Lasting Therapeutic Responses from Allogeneic Therapy – Is Redosing the Way to Go? 8:30 am

Examine the role of redosing in sustaining therapeutic efficacy and preventing disease relapse in patients receiving allogeneic therapies How do we determine if multiple doses are needed and if so, how do we determine how many? Is it better to use a one and done model or plan for multiple doses? Analyze the impact of treatment…Read more

day: Conference Day Two

Upscaling & Transferring Manufacturing of an Allogeneic Active Immune Therapy in Preparation for Commercialization 10:30 am

Discussing key strategies to upscale manufacturing of an allogeneic dendritic cell cancer vaccine by partnering with CDMOs Vididencel is a maintenance immunotherapy designed to improve relapse-free and overall survival in AML Sharing strategies for a smooth tech transfer to take product manufacture to a larger levelRead more

day: Day Two - Track B AM

Panel Discussion: Key Considerations for Commercial Scale Manufacturing 11:30 am

Dive into key factors required to realize commercial scale manufacturing Understanding when the right time for process lock is Discuss whether to involve CDMOs, when to do so, and how to assess readiness for external manufacturingRead more

day: Day Two - Track B AM